Table 3.

Comparison of lipid distribution adjusted to the CHOICE distribution of age, race, gender, and prevalent cardiovascular disease, stratified by lipid-lowering medication usea

LipidCHOICE CohortNHANES III Population
On Lipid- Lowering Medication (n = 169)Not on Lipid- Lowering Medication (n = 872)Not on Lipid-Lowering Medication (n = 19,194)
Estimates (SE)Estimates (SE)Unadjusted NHANES III estimates (SE)Estimates adjusted to CHOICEa (SE)
a NHANES, National Health and Nutrition Examination; SE, standard error.
b NHANES III estimates were adjusted to the age (by decade), gender, race, and prevalent atherosclerotic cardiovascular disease distributions of the CHOICE cohort.
On lipid-lowering medication (%)16 (1.1)2.8 (0.2)8.4 (0.7)
Mean total cholesterol (mg/dl)201 (4.1)186 (1.7)201 (0.7)215 (1.3)
Total cholesterol, NCEP Category
    <200 (normal)57 (4.3)65 (1.8)52 (0.9)38 (1.4)
    200–239 (borderline)20 (3.5)23 (1.5)30 (0.8)35 (1.1)
    ≥240 (high)23 (3.7)12 (1.2)18 (0.6)27 (1.3)
Mean LDL cholesterol (mg/dl)111 (4.1)106 (1.5)126 (0.8)136 (1.4)
High LDL cholesterol (% ≥160 mg/dl)14 (3.2)8.3 (1.1)17 (0.8)26 (1.7)
Mean apolipoprotein-B (mg/dl)100 (2.8)91 (1.1)103 (0.8)111 (1.0)
High apolipoprotein-B (% ≥140 mg/dl)9 (2.5)5 (0.8)9 (0.6)14 (1.1)
Mean HDL cholesterol (mg/dl)43 (1.4)43 (0.6)51 (0.3)50 (0.5)
Low HDL cholesterol (% <40 mg/dl)48 (4.4)45 (1.8)23 (0.8)28 (1.1)
Total HDL:cholesterol ratio5.2 (0.2)4.7 (0.1)4.3 (0.04)4.8 (0.06)
Mean apolipoprotein-A1 (mg/dl)138 (3.2)131 (1.1)143 (1.0)144 (1.0)
Mean triglycerides (mg/dl)250 (14)189 (5)139 (2.0)162 (2.7)
High triglycerides (% ≥200 mg/dl)52 (4.4)34 (1.7)17 (0.6)23 (0.9)
High triglycerides (≥200 mg/dl) and low HDL (<40 mg/dl) (%)30 (4.0)24 (1.6)9 (0.4)13 (0.9)